Reduced Incidence and Severity of Acute Radiation Mucositis by WF10 (IMMUNOKINE(cid:31)) as Adjunct to Standard of Cure in the Management of Head & Neck Cancer Patients
Somkit Penpattanagul MD*
Affiliation : * Department of Therapeutic Radiology, Udonthani Cancer Center, Udonthani
Objective : To evaluate the role of WF10-immunotherapy in reducing oro-pharyngeal complications in head
and neck cancer chemoradiotherapy.
Materials and Methods : Thirteen patients were enrolled and assigned either to WF10- (n = 6) or control group
(n = 7). After completion of their initial (neoadjuvant) chemotherapy, patients received WF10 intravenous
infusions at 0.5 mL/kg body weight/day for five consecutive days and repeated every 3 weeks, concomitantly
to standard radiotherapy (6,600-7,500 cGy, 200 cGy/day). Control patients received radiotherapy alone.
Results : Patients in the WF10-group had a lower incidence of oro-pharyngeal complications grade > 2,
including oral mucositis (1 vs. 5), dysphagia (2 vs. 7), oral pain (3 vs. 5), taste alteration (4 vs. 6) and weight
loss (2 vs. 4). The statistical significances were achieved for the parameters of oral mucositis (p = 0.048) and
dysphagia (p = 0.009).
Conclusion : WF10 appears to reduce severity of oro-pharyngeal complications associated with standard
chemoradiotherapy for head and neck cancer.
Keywords : Tetrachlorodecaoxygen (TCDO iv, WF10), Chemotherapy, Radiotherapy, Mucositis, Head and Neck Cancer
